Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 10/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397845 | 1.00 | SLC9A1 (0.54) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL25909192 | 0.85 | KDM1A (0.61) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL22654463 | 0.85 | KDM1A (0.61) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL14306847 | 0.85 | HTR2A (0.54) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL7655989 | 0.84 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL18272446 | 0.84 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL248384 | 0.84 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL247915 | 0.84 | SLC9A1 (0.48) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL12915852 | 0.84 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL248385 | 0.84 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110437092-B | Preparation method of ticagrelor key intermediate aromatic cyclopropane amide | 泓博智源(开原)药业有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-110437092-A | A kind of preparation method of ticagrelor key intermediate aromatic cyclopropane amide | HONGBO ZHIYUAN KAIYUAN PHARMACEUTICAL CO LTD | 2019-11-12 | — | — | CN | disclosed |
| EP-2644591-A1 | Optically active 2-aryl cyclopropane carboxamide intermediates | Astrazeneca AB (SE) | 2013-10-02 | — | — | EP | disclosed |
| EP-2644591-A1 | Optically active 2-aryl cyclopropane carboxamide intermediates | Astrazeneca AB (SE) | 2013-10-02 | — | — | EP | disclosed |
| US-8278475-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2012-10-02 | — | — | US | disclosed |
| US-20120136167-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2012-05-31 | — | — | US | disclosed |
| US-8026396-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20110137056-A1 | Chemical Process For Preparation Of Intermediates | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110137056-A1 | Chemical Process For Preparation Of Intermediates | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7863469-B2 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-20100331575-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-7790927-B2 | Using hypochlorite in water in presence of alkali metal hydroxide | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| EP-2049462-A1 | CHEMICAL PROCESS FOR PREPARATION OF AROMATIC CYCLOPROPANE ESTERS AND AMIDES | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | disclosed |
| WO-2008018823-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018822-A1 | CHEMICAL PROCESS FOR PREPARATION OF AROMATIC CYCLOPROPANE ESTERS AND AMIDES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018822-A1 | CHEMICAL PROCESS FOR PREPARATION OF AROMATIC CYCLOPROPANE ESTERS AND AMIDES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | SLC9A1 4551/4885HTR2A 302/4885HTR2C 118/4885 |
| US-20100331575-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | SLC9A1 4551/4885HTR2A 302/4885HTR2C 118/4885 |
| US-20110137056-A1 | Chemical Process For Preparation Of Intermediates | DHPS, CYP3A5, CYP3A43 | SLC9A1 4532/4885HTR2A 3056/4885HTR2C 2268/4885 |
| US-20120136167-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP2S1, CYP1B1 | SLC9A1 4566/4885HTR2A 315/4885HTR2C 112/4885 |
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | TBXA2R, F2R, F2 | SLC9A1 3299/4885HTR2A 372/4885HTR2C 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.